Guenther Koehne

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. doi request reprint Allogeneic hematopoietic stem cell transplantation for multiple myeloma: curative but not the standard of care
    Guenther Koehne
    Adult Bone Marrow Transplantation Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, New York 10065, USA
    Curr Opin Oncol 24:720-6. 2012
  2. ncbi request reprint Quantitation, selection, and functional characterization of Epstein-Barr virus-specific and alloreactive T cells detected by intracellular interferon-gamma production and growth of cytotoxic precursors
    Guenther Koehne
    Department of Pediatrics, Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Blood 99:1730-40. 2002
  3. ncbi request reprint [131I]FIAU labeling of genetically transduced, tumor-reactive lymphocytes: cell-level dosimetry and dose-dependent toxicity
    Pat Zanzonico
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, USA
    Eur J Nucl Med Mol Imaging 33:988-97. 2006
  4. ncbi request reprint Adoptive transfer of antigen-specific T-cells of donor type for immunotherapy of viral infections following allogeneic hematopoietic cell transplants
    RICHARD J O'REILLY
    Department of Pediatrics, Memorial Sloan Kettering Cancer Institute, New York, NY, USA
    Immunol Res 38:237-50. 2007
  5. pmc Reduced late mortality risk contributes to similar survival after double-unit cord blood transplantation compared with related and unrelated donor hematopoietic stem cell transplantation
    Doris M Ponce
    Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Biol Blood Marrow Transplant 17:1316-26. 2011
  6. doi request reprint Long-term survival in patients with peripheral T-cell non-Hodgkin lymphomas after allogeneic hematopoietic stem cell transplant
    Jenna D Goldberg
    Adult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Leuk Lymphoma 53:1124-9. 2012
  7. pmc A novel reduced-intensity conditioning regimen induces a high incidence of sustained donor-derived neutrophil and platelet engraftment after double-unit cord blood transplantation
    Doris M Ponce
    Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Biol Blood Marrow Transplant 19:799-803. 2013
  8. pmc Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation
    Ekaterina Doubrovina
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Blood 119:2644-56. 2012
  9. pmc Successful treatment of EBV-associated posttransplantation lymphoma after cord blood transplantation using third-party EBV-specific cytotoxic T lymphocytes
    Juliet N Barker
    Department of Medicine, Allogeneic Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Blood 116:5045-9. 2010
  10. pmc Recombinant human interleukin-7 (CYT107) promotes T-cell recovery after allogeneic stem cell transplantation
    Miguel Angel Perales
    Adult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Blood 120:4882-91. 2012

Collaborators

Detail Information

Publications18

  1. doi request reprint Allogeneic hematopoietic stem cell transplantation for multiple myeloma: curative but not the standard of care
    Guenther Koehne
    Adult Bone Marrow Transplantation Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, New York 10065, USA
    Curr Opin Oncol 24:720-6. 2012
    ..In this review, we summarize the emerging data on allo HSCT and provide suggestions for its optimal role in the treatment of myeloma...
  2. ncbi request reprint Quantitation, selection, and functional characterization of Epstein-Barr virus-specific and alloreactive T cells detected by intracellular interferon-gamma production and growth of cytotoxic precursors
    Guenther Koehne
    Department of Pediatrics, Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Blood 99:1730-40. 2002
    ..Strikingly, the CD4(+)IFN-gamma(+) cell fractions were not cytotoxic against EBV-transformed or allogeneic targets...
  3. ncbi request reprint [131I]FIAU labeling of genetically transduced, tumor-reactive lymphocytes: cell-level dosimetry and dose-dependent toxicity
    Pat Zanzonico
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, USA
    Eur J Nucl Med Mol Imaging 33:988-97. 2006
    ....
  4. ncbi request reprint Adoptive transfer of antigen-specific T-cells of donor type for immunotherapy of viral infections following allogeneic hematopoietic cell transplants
    RICHARD J O'REILLY
    Department of Pediatrics, Memorial Sloan Kettering Cancer Institute, New York, NY, USA
    Immunol Res 38:237-50. 2007
    ..New more predictable strategies are under development, which should allow such therapies to be broadly applicable...
  5. pmc Reduced late mortality risk contributes to similar survival after double-unit cord blood transplantation compared with related and unrelated donor hematopoietic stem cell transplantation
    Doris M Ponce
    Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Biol Blood Marrow Transplant 17:1316-26. 2011
    ..482). These data provide strong support for the further investigation of double-unit CB grafts as an alternative hematopoietic stem cell source...
  6. doi request reprint Long-term survival in patients with peripheral T-cell non-Hodgkin lymphomas after allogeneic hematopoietic stem cell transplant
    Jenna D Goldberg
    Adult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Leuk Lymphoma 53:1124-9. 2012
    ..These data demonstrate that allogeneic transplant is a viable option for the treatment of T-NHL and merits prospective evaluation...
  7. pmc A novel reduced-intensity conditioning regimen induces a high incidence of sustained donor-derived neutrophil and platelet engraftment after double-unit cord blood transplantation
    Doris M Ponce
    Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Biol Blood Marrow Transplant 19:799-803. 2013
    ..It also represents a promising alternative to high-dose conditioning in younger patients...
  8. pmc Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation
    Ekaterina Doubrovina
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Blood 119:2644-56. 2012
    ....
  9. pmc Successful treatment of EBV-associated posttransplantation lymphoma after cord blood transplantation using third-party EBV-specific cytotoxic T lymphocytes
    Juliet N Barker
    Department of Medicine, Allogeneic Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Blood 116:5045-9. 2010
    ..Such therapy may also be applicable to the treatment of other infections and residual or recurrent malignancy after CBT...
  10. pmc Recombinant human interleukin-7 (CYT107) promotes T-cell recovery after allogeneic stem cell transplantation
    Miguel Angel Perales
    Adult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Blood 120:4882-91. 2012
    ..Our results indicate that r-hIL-7 can enhance immune recovery after a T cell-depleted allo-HSCT without causing significant GVHD or other serious toxicity (www.clinicaltrials.gov; NCT00684008)...
  11. doi request reprint WT1-specific T-cell responses in high-risk multiple myeloma patients undergoing allogeneic T cell-depleted hematopoietic stem cell transplantation and donor lymphocyte infusions
    Eleanor M Tyler
    Immunology and Microbial Pathogenesis Program, Weill Cornell Graduate School of Medical Sciences, New York, NY, USA
    Blood 121:308-17. 2013
    ....
  12. doi request reprint T cell-depleted stem cell transplantation for adults with high-risk acute lymphoblastic leukemia: long-term survival for patients in first complete remission with a decreased risk of graft-versus-host disease
    Jenna D Goldberg
    Adult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Biol Blood Marrow Transplant 19:208-13. 2013
    ..15 (95% CI, 0.04-0.26), and that of extensive chronic GVHD at 2 and 5 years was 0.05 (95% CI, 0-11.6). We demonstrate OS and DFS rates that compare favorably to unmodified allo-HSCT with lower rates of GVHD...
  13. pmc T cell-depleted unrelated donor stem cell transplantation provides favorable disease-free survival for adults with hematologic malignancies
    Ann A Jakubowski
    Adult Allogeneic Bone Marrow Transplant Service, Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, New York, New York 10065, USA
    Biol Blood Marrow Transplant 17:1335-42. 2011
    ..There was 1 late graft failure. This study demonstrates durable engraftment with a low overall incidence of GVHD. Its curative potential is reflected in the remarkably low relapse rate at 4 years...
  14. doi request reprint Novel strategies for adoptive therapy following HLA disparate transplants
    RICHARD J O'REILLY
    Marrow Transplantation Program, Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Best Pract Res Clin Haematol 24:381-91. 2011
    ..These approaches may thus provide new, immediately accessible resources for the generation and broad application of immune cell therapies to treat and prevent severe viral diseases post transplant...
  15. doi request reprint Adoptive transfer of unselected or leukemia-reactive T-cells in the treatment of relapse following allogeneic hematopoietic cell transplantation
    RICHARD J O'REILLY
    The Transplantation and Leukemia Service of the Department of Medicine and the Immunology and Molecular Pharmacology Programs at Memorial Sloan Kettering Cancer Center, United States
    Semin Immunol 22:162-72. 2010
    ....
  16. ncbi request reprint Generation of CMV-specific T lymphocytes using protein-spanning pools of pp65-derived overlapping pentadecapeptides for adoptive immunotherapy
    Deepa Trivedi
    Allogenic Bone Marrow Transplantation Service, Department of Pediatrics, Transplantation Biology Laboratory, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Blood 105:2793-801. 2005
    ....
  17. ncbi request reprint Rituximab therapy of lymphoma is enhanced by orally administered (1-->3),(1-->4)-D-beta-glucan
    Shakeel Modak
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, USA
    Leuk Res 29:679-83. 2005
    ..No clinical toxicity was observed. The therapeutic efficacy and lack of toxicity of this combination supports further investigation into its clinical utility...
  18. ncbi request reprint Serial in vivo imaging of the targeted migration of human HSV-TK-transduced antigen-specific lymphocytes
    Guenther Koehne
    Allogeneic Bone Marrow Transplantation Service, Department of Pediatrics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Nat Biotechnol 21:405-13. 2003
    ..This technique for imaging the migration of ex vivo-transduced antigen-specific T cells in vivo is informative, nontoxic, and potentially applicable to humans...